Nancy Wysenski Acquires 75 Cytokinetics Shares Through Equity Retainer Program

Nancy Wysenski, a director of Cytokinetics Inc., acquired 75 shares of common stock on July 15, 2026, through the company's Equity in lieu of Cash Retainer Program. The shares were granted at a price of $82.62 per share and were fully vested at the time of grant. This transaction increased her total holdings to 33,992 shares. The filing represents a routine equity grant to a board member as part of director compensation, where equity is provided instead of cash retainers. The transaction was filed on July 16, 2026, and was signed by John Faurescu as attorney-in-fact for Ms. Wysenski. Such equity-based compensation arrangements are common for corporate directors and help align their interests with shareholders.